Noninvasive Negative Pressure Ventilation to Support Failing Fontan Physiology
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Patients with Fontan physiology with clinical evidence of Fontan failure as defined by those with one of the following in addition to Fontan circulation: New York Heart Association Class II, fluid retention, cyanosis, protein losing enteropathy, renal/hepatic dysfunction and/or subjectively qualify for hemodynamic assessment (by primary cardiologist).
Exclusion Criteria:
- Patients which will likely require intubation for catheterization
- Severely depressed systemic ventricular systolic function
- Baseline airway obstruction
- Plastic bronchitis
- Significant OUTFLOW obstruction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hayek RTX ventilator
Participants will receive noninvasive negative pressure ventilation.
|
Participants will receive Noninvasive negative pressure from the Hayek RTX ventilator for 30 minutes during diagnostic catheterization procedure.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hemodynamics as characterized by change in pulmonary artery pressure
Time Frame: Baseline, 45 Minutes
|
Pulmonary artery wedge pressure will be measured in millimeters of mercury (mmHg) at baseline and completion of noninvasive negative pressure ventilation.
|
Baseline, 45 Minutes
|
|
Hemodynamics as characterized by change in pulmonary blood flow
Time Frame: Baseline, 45 Minutes
|
Change in pulmonary blood flow will be measured at baseline and completion of noninvasive negative pressure ventilation.
|
Baseline, 45 Minutes
|
|
Hemodynamics as characterized by change in systemic arterial saturation
Time Frame: Baseline, 45 Minutes
|
Systemic arterial saturation measures the amount of oxygen in the blood stream.
Systemic arterial saturation will be registered at baseline and completion of noninvasive negative pressure ventilation.
|
Baseline, 45 Minutes
|
|
Hemodynamics as characterized by change in cardiac output
Time Frame: Baseline, 45 Minutes
|
Cardiac output will be measured in liters per minute at baseline and completion of noninvasive negative pressure ventilation
|
Baseline, 45 Minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: David Peng, MD, University of Michigan
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HUM00131186
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Congenital Heart Disease
-
NCT02752191CompletedPediatric Congenital Heart Disease
-
NCT06784440RecruitingAdult Congenital Heart Disease | Congenital Heart Disease (CHD) | Pediatric Congenital Heart Disease | Heart Transplant Patients
-
NCT04125550CompletedPediatric HD | Cyanotic Congenital Heart Disease
-
NCT06031831Active, not recruitingCongenital Heart Disease | Pediatric
-
NCT03303248CompletedCongenital Heart Disease | Pediatric Congenital Heart Disease | Transition
-
NCT01706497CompletedPediatric Congenital Heart Surgery
-
NCT04068987UnknownCardiomyopathies | Cardiac Disease | Congenital Disorders | Pediatric Disease
-
NCT05665712CompletedPediatric ALL | Congenital Heart Disease | ERAS
-
NCT06626672RecruitingPediatric ALL | Congenital Heart Disease
-
NCT07556185Not yet recruitingAcquired Heart Disease | Pulmonary Hypertension | Congenital Heart Disease (CHD) | Post Cardiac Surgery | Pediatric Heart Failure
Clinical Trials on Hayek RTX ventilator
-
NCT03251742Completed
-
NCT00331656UnknownPneumonia | Chronic Obstructive Pulmonary Disease | Neuromuscular Diseases | Respiratory Insufficiency | Pulmonary Edema
-
NCT05350332RecruitingObstructive Sleep Apnea
-
NCT07439887Recruiting
-
NCT06460844Active, not recruitingRetinitis Pigmentosa | Choroideremia
-
NCT05219578TerminatedNon Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Cutaneous Melanoma | TNBC - Triple-Negative Breast Cancer
-
NCT04110496TerminatedPhenylketonurias
-
NCT04672980TerminatedCervical Cancer | Head and Neck Cancer | Anal Cancer
-
NCT03226574Completed